Evelo proposes $100M IPO

Microbiome company Evelo Biosciences Inc. (Cambridge, Mass.) proposed to raise $100 million in an IPO on NASDAQ underwritten by Morgan Stanley, Cowen, BMO Capital Markets and JMP Securities.

Evelo has a portfolio of preclinical monoclonal microbials that interact with gut cells to modulate systemic immunology and biology to treat cancer and inflammatory diseases (see BioCentury Innovations, Dec. 3, 2015)...